Search

Researchers from Tehran Islamic Azad University of Medical Sciences have synthesized and identified magnetic nickel oxide nanoparticles for the pre-concentration and determination of gemfibrozil in human serum samples, pharmaceutical wastewater, and drugs. The nanoparticles were characterized using Fourier transform infrared spectrum (FTIR), X-ray diffraction (XRD), and scanning electron microscope (SEM). The method was successfully used to determine gemfibrozil using a UV-Vis spectrometer, and the results were compared to the standard high-performance liquid chromatography (HPLC) method, showing no significant difference between the two methods. The research provides valuable insights into the use of nanoparticles for solid phase extraction in pharmaceutical analysis. [Extracted from the article]

Researchers from Rush University Medical Center have published a study on experimental autoimmune encephalomyelitis (EAE), a disease that serves as a model for multiple sclerosis (MS). The study found that gemfibrozil, a lipid-lowering drug, was effective in preserving the integrity of the blood-brain barrier and blood-spinal cord barrier, reducing the infiltration of mononuclear cells into the central nervous system, and inhibiting the disease process of EAE in mice. The study also showed that gemfibrozil protected regulatory T cells, which play a critical role in the disease process of EAE/MS. The findings suggest that gemfibrozil may have implications for the treatment of multiple sclerosis. [Extracted from the article]

A study conducted at Visvesvaraya Technological University in Bengaluru, India, focused on the use of nickel oxide nanoparticles (NiONPs) combined with multiwalled carbon nanotubes (MWCNTs) to create a modified carbon paste electrode (MCPE) sensor. This sensor was used to analyze the drug Gemfibrozil in pharmaceutical formulations and human urine samples. The sensor exhibited excellent electrochemical behavior and demonstrated high sensitivity, a wide linear range, and long-term stability. Additionally, the nanoparticles showed promising antibacterial activity against various microbes. The research provides valuable insights into the application of nanotechnology in drug analysis and antimicrobial research. [Extracted from the article]

A recent study conducted at Rush University Medical Center in Chicago has found that the lipid-lowering drug gemfibrozil may protect mice from Tay-Sachs disease. Tay-Sachs disease is a progressive neurodegenerative disorder characterized by the deficiency of the lysosomal b-hexosaminidase enzyme and the storage of GM2 ganglioside. The study showed that oral administration of gemfibrozil reduced glial activation and inflammation, decreased the accumulation of GM2 gangliosides, improved behavioral performance, and increased the life expectancy of mice with Tay-Sachs disease. The researchers also found that gemfibrozil's effects were dependent on the peroxisome proliferator-activated receptor a (PPARa). This research provides valuable insights into potential treatments for Tay-Sachs disease. [Extracted from the article]

A study conducted by researchers at Medical University in Lublin, Poland, explores the effects of fenofibrate and gemfibrozil, two commonly used triglyceride-lowering drugs, on kynurenic acid (KYNA) production and kynurenine aminotransferase (KAT) activity in rat kidneys. The study found that both drugs significantly inhibited KYNA synthesis in rat kidney homogenates, suggesting a potential role in kidney function protection beyond their known anti-hyperlipidemic effect. The research highlights the importance of kidney function in cardiovascular risk and the potential of these drugs in treating lipid abnormalities in patients with kidney disorders. [Extracted from the article]

Keywords: Antibiotics; Antihyperlipidemic Agents; Antiinfectives; Carboxylic Acids; Clofibric Acid; Cyclooxygenase Inhibitors; Dermatological Agents; Diclofenac; Diclofenac Therapy; Drugs and Therapies; Erythromycin Therapy; Fibric Acid Derivatives; Gemfibrozil; Gemfibrozil Therapy; Health and Medicine; Macrolide Derivatives; Macrolides; NSAID; Ophthalmic Antiinfectives; Ophthalmic Antiinflammatory Agents; Ophthalmic Preparations; Organic Chemicals; Pentanoic Acids; Pharmaceuticals; Phenylacetates; Topical Acne Agents EN Antibiotics Antihyperlipidemic Agents Antiinfectives Carboxylic Acids Clofibric Acid Cyclooxygenase Inhibitors Dermatological Agents Diclofenac Diclofenac Therapy Drugs and Therapies Erythromycin Therapy Fibric Acid Derivatives Gemfibrozil Gemfibrozil Therapy Health and Medicine Macrolide Derivatives Macrolides NSAID Ophthalmic Antiinfectives Ophthalmic Antiinflammatory Agents Ophthalmic Preparations Organic Chemicals Pentanoic Acids Pharmaceuticals Phenylacetates Topical Acne Agents 2676 2676 1 10/09/23 20231013 NES 231013 2023 OCT 13 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators discuss new findings in ophthalmic antiinflammatory agents. For more information on this research see: Treatment performance and microbial community structure in an aerobic granular sludge sequencing batch reactor amended with diclofenac, erythromycin, and gemfibrozil. [Extracted from the article]

In literature, the lipid-based drug delivery system has received substantial coverage for improving drug solubility, permeability, and bioavailability. Keywords: Antihyperlipidemic Agents; Carboxylic Acids; Clofibric Acid; Drugs and Therapies; Fibric Acid Derivatives; Gemfibrozil; Gemfibrozil Therapy; Health and Medicine; Hyperlipidemias; Lipid Research; Lipids; Lipoproteins; Nanotechnology; Organic Chemicals; Pentanoic Acids; Pharmaceuticals EN Antihyperlipidemic Agents Carboxylic Acids Clofibric Acid Drugs and Therapies Fibric Acid Derivatives Gemfibrozil Gemfibrozil Therapy Health and Medicine Hyperlipidemias Lipid Research Lipids Lipoproteins Nanotechnology Organic Chemicals Pentanoic Acids Pharmaceuticals 610 610 1 10/09/23 20231013 NES 231013 2023 OCT 13 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- New study results on hyperlipidemias have been published. [Extracted from the article]

Keywords: Antihyperlipidemics; Bezafibrate; Butyrates; Butyric Acids; Carboxylic Acids; Clofibric Acid; Drugs and Therapies; Organic Chemicals; Pharmacology; Risk and Prevention EN Antihyperlipidemics Bezafibrate Butyrates Butyric Acids Carboxylic Acids Clofibric Acid Drugs and Therapies Organic Chemicals Pharmacology Risk and Prevention 717 717 1 08/07/23 20230808 NES 230808 2023 AUG 11 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Researchers detail new data in pharmacology. Bezafibrate, Butyrates, Butyric Acids, Carboxylic Acids, Clofibric Acid, Antihyperlipidemics, Drugs and Therapies, Organic Chemicals, Pharmacology, Risk and Prevention. [Extracted from the article]

Chicago, State:Illinois, United States, North and Central America, Antihyperlipidemic Agents, Biological Factors, Biological Pigments, Carboxylic Acids, Ceroid, Clofibric Acid, Drugs and Therapies, Fibric Acid Derivatives, Gemfibrozil, Gemfibrozil Therapy, Health and Medicine, Lipid Metabolism Disorders, Lipofuscin, Nervous System Diseases and Conditions, Neuronal Ceroid Lipofuscinoses, Lipidoses, Nutritional and Metabolic Diseases and Conditions, Organic Chemicals, Pentanoic Acids, Pharmaceuticals Keywords: Chicago; State:Illinois; United States; North and Central America; Antihyperlipidemic Agents; Biological Factors; Biological Pigments; Carboxylic Acids; Ceroid; Clofibric Acid; Drugs and Therapies; Fibric Acid Derivatives; Gemfibrozil; Gemfibrozil Therapy; Health and Medicine; Lipid Metabolism Disorders; Lipidoses; Lipofuscin; Nervous System Diseases and Conditions; Neuronal Ceroid Lipofuscinoses; Nutritional and Metabolic Diseases and Conditions; Organic Chemicals; Pentanoic Acids; Pharmaceuticals EN Chicago State:Illinois United States North and Central America Antihyperlipidemic Agents Biological Factors Biological Pigments Carboxylic Acids Ceroid Clofibric Acid Drugs and Therapies Fibric Acid Derivatives Gemfibrozil Gemfibrozil Therapy Health and Medicine Lipid Metabolism Disorders Lipidoses Lipofuscin Nervous System Diseases and Conditions Neuronal Ceroid Lipofuscinoses Nutritional and Metabolic Diseases and Conditions Organic Chemicals Pentanoic Acids Pharmaceuticals 1676 1676 1 05/08/23 20230512 NES 230512 2023 MAY 12 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- New research on Nervous System Diseases and Conditions - Neuronal Ceroid Lipofuscinoses is the subject of a report. According to the news reporters, the research concluded: "These results suggest that activation of PPARa may be beneficial for JNCL and that gemfibrozil may be repurposed for the treatment of this incurable disease.". [Extracted from the article]

Keywords for this news article include: College of Engineering, Andhra Pradesh, India, Asia, Antihyperlipidemic Agents, Pharmaceuticals, Clofibric Acid, Pentanoic Acids, Carboxylic Acids, Organic Chemicals, Drugs and Therapies, Gemfibrozil Therapy, Health and Medicine, Fibric Acid Derivatives. Keywords: Antihyperlipidemic Agents; Carboxylic Acids; Clofibric Acid; Drugs and Therapies; Fibric Acid Derivatives; Gemfibrozil; Gemfibrozil Therapy; Health and Medicine; Organic Chemicals; Pentanoic Acids; Pharmaceuticals EN Antihyperlipidemic Agents Carboxylic Acids Clofibric Acid Drugs and Therapies Fibric Acid Derivatives Gemfibrozil Gemfibrozil Therapy Health and Medicine Organic Chemicals Pentanoic Acids Pharmaceuticals 340 340 1 03/23/23 20230317 NES 230317 2023 MAR 17 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Fresh data on antihyperlipidemic agents are presented in a new report. Antihyperlipidemic Agents, Carboxylic Acids, Clofibric Acid, Drugs and Therapies, Fibric Acid Derivatives, Gemfibrozil Therapy, Health and Medicine, Organic Chemicals, Pentanoic Acids, Pharmaceuticals, Gemfibrozil. [Extracted from the article]

Antihyperlipidemic Agents, Carboxylic Acids, Clofibric Acid, Drugs and Therapies, Fibric Acid Derivatives, Gemfibrozil, Gemfibrozil Therapy, Health and Medicine, Organic Chemicals, Pentanoic Acids, Pharmaceuticals According to news originating from Homburg, Germany, by NewsRx editors, the research stated, "Gemfibrozil is a drug that has been used for over 40 years to lower triglycerides in blood." Keywords: Antihyperlipidemic Agents; Carboxylic Acids; Clofibric Acid; Drugs and Therapies; Fibric Acid Derivatives; Gemfibrozil; Gemfibrozil Therapy; Health and Medicine; Organic Chemicals; Pentanoic Acids; Pharmaceuticals EN Antihyperlipidemic Agents Carboxylic Acids Clofibric Acid Drugs and Therapies Fibric Acid Derivatives Gemfibrozil Gemfibrozil Therapy Health and Medicine Organic Chemicals Pentanoic Acids Pharmaceuticals 2458 2458 1 03/24/23 20230228 NES 230228 2023 MAR 3 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Current study results on antihyperlipidemic agents have been published. [Extracted from the article]